# A Phase 1/2 Study of BA3071 in Patients With Solid Tumors

Source: https://onco.cc/trials/nct05180799/  
OnCo record `nct05180799` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of BA3071, Nivolumab, Pembrolizumab in melanoma, run by BioAtla, Inc., active and no longer recruiting.

## Summary

A Phase 1/2 Study of BA3071 in Patients With Solid Tumors is a phase 1/2 interventional study registered as NCT05180799 by BioAtla, Inc., with 320 participants planned, started 2022-08-03 and due to reach its primary completion in 2025-03-19. Interventions recorded: BA3071, Nivolumab, Pembrolizumab, Pemetrexed (Alimta). Conditions listed: NSCLC, Melanoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05180799
- Phase: 1/2
- Setting: A Phase 1/2 Study of BA3071 in Patients With Solid Tumors
- Sponsor: BioAtla, Inc.
- Enrolled: 320

## Sources

- ClinicalTrials.gov NCT05180799: https://clinicaltrials.gov/study/NCT05180799

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)
- drugs: [BA3071](https://onco.cc/drugs/ba3071/), [Nivolumab](https://onco.cc/drugs/nivolumab/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Pemetrexed](https://onco.cc/drugs/pemetrexed/)

---
JSON: https://onco.cc/api/v1/entities/nct05180799.json